Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/cardiology.2.017
Insights of CECCY Trial: Should Troponin be the Target for Anthracycline Cardiotoxicity Prevention?
- 1Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil
Edimar Alchides Bocchi, email@example.com
Received Date: March 24, 2021
Accepted Date: August 12, 2021
Bocchi EA, Belfort DP, Avila MS. Insights of CECCY Trial: Should Troponin be the Target for Anthracycline Cardiotoxicity Prevention? J Clin Cardiol. 2021; 2(3):46-49.
Copyright: © 2021 Bocchi EA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series
5-fluorouracil (5-FU), an antimetabolite in the fluoropyrimidine class, is the third most commonly used chemotherapeutic agent worldwide for the treatment of solid malignancies . Despite advances in novel cancer therapies, commonly used in combination with fluoropyrimidines, 5-FU remains one of the most effective and safe chemotherapy agents to manage colorectal cancer (CRC).
Advances in oncology such as better access to health care system, earlier cancer diagnosis and new chemotherapies have led to longer survival of oncologic patients over the last decades. However, this population is vulnerable to cardiovascular drug-related adverse events like cardiomyopathy, which leads to heart failure and impairs survival and quality of life.
Immune checkpoint inhibitors (ICIs) are a new type of broad-spectrum antitumor drugs, which mainly include cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitors, programmed cell death protein-1 (PD-1) and its ligand PD-L1 inhibitors. Since 2011, ICIs have been approved for more than 20 kinds of malignant tumors.
High Throughput Image Analysis for Cardiotoxicity Study using Human Pluripotent Stem Cell-Derived Cardiomyocytes
Severe cardiotoxic side-effects are found in patients who are treated with anti-cancer drugs from both earliest chemotherapeutics (for example anthracyclines, such as Doxorubicin) and novel therapeutic compounds, such as monoclonal antibodies and small molecules inhibiting tyrosine kinases; e.g. crizotinib.